Mohamed Sikkander Abdul Razak: Addressing Underdiagnosis of Bleeding Disorders in Women With Heavy Menstrual Bleeding
Mohamed Sikkander Abdul Razak, Professor at GKM College of Engineering Technology, shared Heghine Khachatryan’s post on LinkedIn:
“1. Heavy menstrual bleeding (HMB) is described as:
The most common bleeding manifestation of underlying hemostatic defects, often underdiagnosed.
2. The mechanistic pathway explaining why bleeding occurs involves:
- Endothelial integrity and angiogenesis: estrogen and progesterone cause a fragile endometrium with increased vascular density.
- Primary hemostasis defect: von Willebrand factor (vWF) or platelet dysfunction – impaired adhesion and aggregation.
- Secondary hemostasis impairment: reduced thrombin generation or fibrinolysis – unstable fibrin clot.
- Clinical outcome: excessive and prolonged menstrual bleeding (HMB).
3. Most common causes of HMB are:
- von Willebrand disease (vWD).
- Platelet function disorders.
- Mild factor deficiencies.
4. During pregnancy, hemostatic changes:
- Mask bleeding disorders, but risks resurface as:
- Increased miscarriage (early placental hemostasis failure).
- Postpartum hemorrhage (rapid fibrinolysis plus uterine atony).
- Maternal morbidity (unrecognized vWD or platelet defects).
5. Misdiagnosis of HMB can lead to:
- Delayed diagnosis.
- Severe anemia.
- Obstetric and surgical complications.
- Preventable morbidity.
6. HMB is often the:
First and only warning sign of a bleeding disorder.
7. Call to action for HMB management:
Hematologic evaluation is indicated in ALL women with HMB, especially:
- Adolescents.
- Those with iron deficiency or bleeding history.
- Those planning pregnancy or surgery.
8. Key message about HMB:
It is not a ‘gynecologic’ issue; it is a hemostatic disorder until proven otherwise.”
Heghine Khachatryan, Editor-in-Chief of Hemostasis Today, Head of Hemophilia and Thrombosis Center at Yeolyan Hematology and Oncology Center, shared a post on LinkedIn:
“Heavy menstrual bleeding is not ‘normal’ — it is often missed pathology.
For too long, heavy menstrual bleeding (HMB) has been normalized, underestimated, and frequently misdiagnosed.
Behind what is often dismissed as a ‘gynecological issue’, there may be an underlying hemostatic disorder — including von Willebrand disease, platelet function defects, or other coagulation abnormalities.
The clinical reality is concerning:
Many women remain undiagnosed for years, presenting later with anemia, perioperative bleeding, or complications during pregnancy and childbirth.
Pregnancy introduces an additional layer of complexity.
Hemostasis is dynamically altered, and in women with unrecognized bleeding disorders, this may result in:
- increased risk of miscarriage
- postpartum hemorrhage
- preventable maternal morbidity
Misdiagnosis is not benign — it is systemic failure.
We must shift from symptom-based reassurance to structured hemostatic evaluation, especially in:
- adolescents with HMB
- women with iron deficiency
- patients with bleeding history prior to surgical or reproductive interventions
This is not only a clinical issue — it is a matter of health equity, awareness, and diagnostic capacity.
The time has come to integrate hemostasis into routine women’s health assessment — not as an exception, but as a standard.”

Other posts featuring Mohamed Sikkander Abdul Razak on Hemostasis Today.
-
May 23, 2026, 16:55Rahul Bhargava: Ensure Equal Recognition of Clinical Haematologists in Blood Cancer Clinical Trials
-
May 23, 2026, 16:44Brian O Mahony: World Haemophilia Day Receives Global WHO Recognition
-
May 23, 2026, 16:44Yusuf Hameed: Gene Therapy Could Reduce Lifetime Treatment Burden in Hemophilia A
-
May 23, 2026, 16:43Chokri Ben Lamine: Pacritinib Is a Key JAK Inhibitor for Cytopenic Myelofibrosis
-
May 23, 2026, 16:42Bartosz Hudzik: Bleeding Risk Alone Should Not Determine Treatment Intensity
-
May 23, 2026, 16:42Shimels Tessema: Celebrating the WHA Resolution on Hemophilia and Other Bleeding Disorders
-
May 23, 2026, 16:38José Octavio Alva Bucio: Securing the Future of Plasma and Blood-Derived Medicines
-
May 23, 2026, 16:33Why Are We Dismantling What Powers Humanity and the Global Economy? – ASH
-
May 23, 2026, 16:24Marc Wittwer: A Practical Viscoelastic-Guided Algorithm for Trauma-Induced Coagulopathy in Clinical Workflow